<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00991718</url>
  </required_header>
  <id_info>
    <org_study_id>SHH4683g</org_study_id>
    <nct_id>NCT00991718</nct_id>
  </id_info>
  <brief_title>A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential</brief_title>
  <official_title>A Phase I, Open-Label Absorption, Distribution, Metabolism, and Excretion (ADME) Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is an open-label, Phase I, single-center, single-dose administration study to determine&#xD;
      the absolute bioavailability, clearance, and volume of distribution of GDC-0449 (Part A) and&#xD;
      to determine the routes of excretion and extent of metabolism of GDC-0449 (Part B). Parts A&#xD;
      and B will be conducted sequentially, with â‰¥ 7 days between dosing the sixth subject in Part&#xD;
      A and dosing the first subject in Part B. In each part, 6 healthy female subjects of&#xD;
      non-childbearing potential, between 18 and 65 years of age (inclusive), will be dosed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK (Max observed and time to max plasma concentrations, area under the plasma concentration-time curve, absolute bioavailability, total plasma clearance, vol of dist, plasma terminal phase half-life, cumulative % excretion in urine and feces [Part B])</measure>
    <time_frame>Until study discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety outcome measures (incidence, nature, and severity of adverse events; change in clinical laboratory results; change in vital signs; change in electrocardiogram [ECG]; and change in physical examination findings)</measure>
    <time_frame>Until study discontinuation</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1, subjects received a single oral dose of non-labeled GDC-0449 and a single IV tracer dose of 14C-GDC-0449.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1, subjects received a single oral dose of 14C-GDC-0449.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Days 1-7, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects also received a single IV tracer dose of 14C-GDC-0449.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Days 1-6, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects received a single oral dose of 14C-GDC-0449.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0449 oral capsules (non-labeled)</intervention_name>
    <description>150 mg oral capsule</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0449 IV injection (labeled)</intervention_name>
    <description>10 mcg (in 2 mL) IV dose of 14C-GDC-0449</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDC-0449 oral suspension (labeled)</intervention_name>
    <description>30-mL oral suspension containing 6.5 mcg 14CGDC-0449 and 150 mg GDC-0449</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Non-childbearing potential&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 32 kg/m^2, inclusive&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings on physical&#xD;
             examination, medical history, 12-lead ECG, and vital signs&#xD;
&#xD;
          -  Negative test for drugs of abuse at screening (does not include alcohol) and at&#xD;
             admission to the clinical research facility (does include alcohol)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  History or clinical manifestations of clinically significant metabolic, hepatic,&#xD;
             renal, hematologic, pulmonary, cardiovascular, endocrine, gastrointestinal (including&#xD;
             gastric or duodenal ulcers), urologic, neurologic, inflammatory, or psychiatric&#xD;
             disorders, or cancer&#xD;
&#xD;
          -  History of symptomatic hypotension, idiopathic orthostatic hypotension, or other&#xD;
             autonomous-failure syndromes&#xD;
&#xD;
          -  History of severe physical injury, direct impact trauma, or neurological trauma within&#xD;
             6 months prior to Day -1&#xD;
&#xD;
          -  History of stomach or intestinal surgery, stomach disease, or resection that would&#xD;
             potentially alter absorption and/or excretion of orally administered drugs&#xD;
             (appendectomy, hernia repair, and/or cholecystectomy are allowed)&#xD;
&#xD;
          -  History of alcoholism, drug abuse, or drug addiction (including soft drugs like&#xD;
             cannabis products)&#xD;
&#xD;
          -  Use of any prescription medications/products, including known&#xD;
             enzyme-inducing/inhibiting agents, over-the-counter medication, or other&#xD;
             non-prescription preparations (including supplements, vitamins, minerals,&#xD;
             phytotherapeutic/herbal/ plant-derived preparations, the tryptophans, and St. John's&#xD;
             wort or other hypericum perforatum-containing substance) within 2 weeks prior to Day&#xD;
             -1, with the exception of hormone-replacement therapy&#xD;
&#xD;
          -  Participation in any other investigational drug study in which receipt of an&#xD;
             investigational study drug occurred within 60 days prior to Day -1 or within 5 times&#xD;
             the elimination half-life of the respective drug; participation in a trial involving&#xD;
             administration of ^1^4C-radiolabeled compound(s) within 6 months prior to Day -1;&#xD;
             participation in more than two other drug trials within 1 year prior to Day -1&#xD;
&#xD;
          -  Receipt of any vaccination or immunization within 1 month prior to Day -1&#xD;
&#xD;
          -  Use of any nicotine-containing or nicotine-replacement products within 6 months prior&#xD;
             to Day -1&#xD;
&#xD;
          -  Consumption of alcohol or methylxanthine-containing beverages or food&#xD;
&#xD;
          -  Receipt of blood products within 2 months prior to Day -1&#xD;
&#xD;
          -  Donation of &gt; 100 mL of blood within 60 days prior to Day -1; donation of &gt; 1.0 litres&#xD;
             of blood within 10 months prior to Day -1&#xD;
&#xD;
          -  Irregular defecation pattern, i.e., less than once per 2 days within 6 months prior to&#xD;
             Day -1; acute constipation problems within 3 weeks prior to Day -1 (Part B subjects&#xD;
             only)&#xD;
&#xD;
          -  Poor peripheral venous access&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Low, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>October 6, 2009</study_first_submitted>
  <study_first_submitted_qc>October 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2009</study_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GDC0449</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

